Bayer Aktiengesellschaft

(PINK:BAYZF)

Latest On Bayer Aktiengesellschaft (BAYZF):

Date/Time Type Description Signal Details
2024-04-29 05:57 ESTDividendA dividend of $0.11 has been announced on Feb 2, 2024. It will be paid May 2, 2024 with an ex-dividend date of Apr 29, 2024.Neutral
2023-05-22 01:30 ESTNewsBayer, Orion begin phase 3 trial of Nubeqa to expand prostate cancer indicationN/A
2023-05-22 01:29 ESTNewsDelaware court finds in favor of Bayer in talc disagreement with MerckN/A
2023-05-22 01:29 ESTNewsBayer to invest ~€60M in Ukrainian corn seed production siteN/A
2023-05-22 01:27 ESTNewsActivist Bluebell steps up pressure for Bayer breakup, supervisory board changes - reportN/A
2023-05-22 01:26 ESTNewsBayer's Adempas for high blood pressure in lungs gets EMA nod for use in childrenN/A
2023-05-22 01:26 ESTNewsBayer AG Still Dirt-Cheap, Investors Are Getting Its Pharma Business For 'Free'N/A
2023-05-22 01:25 ESTNewsBayer AG Non-GAAP EPS of €2.95, revenue of €14.39B; targets outlook at lower end of guidanceN/A
2023-05-22 01:25 ESTNewsBayer Q1 sales dips as crop, pharma segments decline; glyphosate prices weigh on outlookN/A
2023-05-22 01:24 ESTNewsBayer AG (BAYZF) Q1 2023 Earnings Call TranscriptN/A
2023-05-22 01:24 ESTNewsBayer's stroke prevention drug asundexian gets 2nd FDA fast track statusN/A
2023-05-22 01:24 ESTNewsCancer-focused Boundless Bio closes $100M funding led by Bayer, RA CapitalN/A
2023-05-22 01:23 ESTNewsBayer Aktiengesellschaft 2023 Q1 - Results - Earnings Call PresentationN/A
2023-05-22 01:23 ESTNewsBayer's kidney disease drug Kerendia gets Chinese regulator nod for expanded useN/A
2023-05-02 05:56 ESTDividendA dividend of $2.4 has been announced on Mar 2, 2023. It will be paid May 4, 2023 with an ex-dividend date of May 2, 2023.Neutral
2023-04-26 11:46 ESTNewsEU publishes proposed reforms for pharma industryN/A
2023-02-28 12:20 ESTNewsBayer AG Non-GAAP EPS of €1.35, revenue of €12BN/A
2022-09-13 20:33 ESTNewsBayer starts executive search to replace CEO Baumann – BloombergN/A
2022-09-03 01:02 ESTNewsBayer in $40M settlement over allegations related to three drugsN/A
2022-05-03 23:22 ESTNewsBayer granted FDA’s priority review for label expansion of prostate cancer therapyN/A
2022-05-02 05:55 ESTDividendA dividend of $2 has been announced on Mar 2, 2022. It will be paid May 4, 2022 with an ex-dividend date of May 2, 2022.Neutral
2022-03-09 15:41 ESTNewsBayer files for expanded use of prostate cancer drug Nubeqa in US, EUN/A
2022-02-28 22:41 ESTNewsBayer Q4 Earnings PreviewN/A
2022-02-19 03:03 ESTNewsBayer raises peak sales estimate for prostate cancer drug after positive phase 3 dataN/A
2022-02-10 18:49 ESTNewsBayer's asundexian gets FDA fast track status for stroke programN/A
2022-02-04 12:57 ESTNewsEvotec regains rights to eliapixant after Bayer ends development; Evotec shares fallN/A
2021-12-07 01:34 ESTNewsRecursion expands collaboration with Bayer on fibrosis researchN/A
2021-08-05 16:58 ESTNewsBayer AG reports Q2 resultsN/A
2021-07-22 11:00 ESTNewsBayer expands oncology portfolio with a deal to acquire Noria and PSMA TherapeuticsN/A
2021-04-28 05:57 ESTDividendA dividend of $2 has been announced on Mar 12, 2021. It will be paid Apr 30, 2021 with an ex-dividend date of Apr 28, 2021.Neutral
2021-02-26 21:08 ESTFinancialsCompany financials have been released.Neutral
2021-02-01 23:35 ESTNewsCureVac ropes in Bayer to boost COVID-19 vaccine productionN/A
2021-01-13 21:13 ESTNewsBayer's blockbuster drugs will not bridge revenue gap led by expired patents: Pharma headN/A
2021-01-12 16:14 ESTNewsFDA accepts Bayer's finerenone application for chronic kidney disease and type 2 diabetesN/A
2021-01-09 01:02 ESTNewsFDA approves Bayer's application to add overall survival benefit to its Nubeqa prescription informationN/A
2020-12-22 11:36 ESTNewsVeracyte and Bayer collaborate in precision oncology; shares jump +17%N/A
2020-12-21 18:06 ESTNewsWuxi Biologics acquires drug substance facility from BayerN/A
2020-12-07 15:14 ESTNewsBayer, Atara inks licensing pact for T-cell therapies for solid tumorsN/A
2020-11-26 22:17 ESTFinancialsCompany financials have been released.Neutral
2020-11-08 01:27 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 17:43 ESTFinancialsCompany financials have been released.Neutral
2020-11-06 21:32 ESTFinancialsCompany financials have been released.Neutral
2020-11-03 14:31 ESTNewsBayer AG reports Q3 resultsN/A
2020-09-26 14:44 ESTFinancialsCompany financials have been released.Neutral
2020-09-17 06:48 ESTFinancialsCompany financials have been released.Neutral
2020-08-14 10:44 ESTFinancialsCompany financials have been released.Neutral
2020-08-06 22:18 ESTFinancialsCompany financials have been released.Neutral
2020-08-06 10:05 ESTFinancialsCompany financials have been released.Neutral
2020-08-05 01:55 ESTNewsBayer AG EPS beats by €0.08, misses on revenueN/A
2020-07-30 18:28 ESTFinancialsCompany financials have been released.Neutral

About Bayer Aktiengesellschaft (BAYZF):

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. Bayer Aktiengesellschaft has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc. and Forschungszentrum Jülich GmbH; strategic research partnership with University of Oxford to develop novel gynecological therapies; and research collaboration agreements with Haplogen GmbH and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.

See Advanced Chart

General

  • Name Bayer Aktiengesellschaft
  • Symbol BAYZF
  • Type Common Stock
  • Exchange PINK
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryDrug Manufacturers-General
  • Full Time Employees 95,955
  • Fiscal Year EndDecember
  • Web URLhttp://www.bayer.com
View More

Valuation

  • Trailing PE 8.63
  • Forward PE 9.12
  • Price/Sales (Trailing 12 Mt.) 1.25
  • Price/Book (Most Recent Quarter) 1.7
  • Enterprise Value Revenue 2.34
  • Enterprise Value EBITDA 10.06
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Profit Margin -25%
  • Return on Assets 4%
  • Return on Equity -40%
  • Earnings Per Share $7.38
  • Revenue Per Share $0
  • Gross Profit 25.67 billion
  • Quarterly Earnings Growth -7%
View More

ESG Rating

  • Rating Date 2019-01-01
  • ESG Score 37.89
  • Environment Score 10.21
  • Social Score 28.72
  • Governance Score 14.47
  • Controversy Level 5
View More

Highlights

  • Market Capitalization 62.14 billion
  • PEG Ratio 4.91
  • Book Value Per Share $59.72
View More

Share Statistics

  • Shares Outstanding 982.42 million
  • Shares Float 982.42 million
  • % Held by Insiders <1%
  • % Held by Institutions 42.75%
View More

Technicals

  • Beta 1.33
  • 52 Week High $84.49
  • 52 Week Low $43.94
  • 50 Day Moving Average 63.81
  • 200 Day Moving Average 59.85
View More

Dividends

  • Forward Annual Dividend Rate $2.4
  • Forward Annual Dividend Yield 3.79%
  • Dividend Date N/A
  • ExDividend Date 2021-04-28
  • Dividend Per Share $3.26
  • Dividend Yield 0%
View More

Bayer Aktiengesellschaft (BAYZF) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount
2024-04-292024-05-022024-04-302024-02-02$0.11
2023-05-022023-05-042023-05-032023-03-02$2.4
2022-05-022022-05-042022-05-032022-03-02$2
2021-04-282021-04-302021-04-292021-03-12$2
2020-04-292020-05-042020-04-302020-02-27$2.8
2019-04-292019-05-022019-04-302019-02-27$2.8
2018-05-252018-05-302018-05-292018-02-27$2.8
2017-05-022017-05-042017-05-032017-02-22$2.7
2016-04-282016-05-022016-04-292016-02-24$2.5

Bayer Aktiengesellschaft (BAYZF) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312020-12-31$N/A$0.37
2020-09-302020-12-31$N/A$0.48
2020-06-302020-09-30$N/A-$9.19$0.44-2189.36%
2020-03-312020-06-30$12.85 billion-$11.00$2.64-516.76%
2019-12-312020-03-31$10.75 billion$1.53$1.2522.54%
2019-09-302019-12-31$9.83 billion-$0.05$1.17-104.2%
2019-06-302019-09-30$13.05 billion$1.10$1.83-39.98%
2019-03-312019-06-30$13.02 billion$0.36$2.66-86.3%
2018-12-312019-03-31$11.06 billion$1.29$2.11-38.86%
2018-09-302018-12-31$11.47 billion-$4.63$0.97-577.8%
2018-06-302018-09-30$11.03 billion$3.32$1.44130.57%
2018-03-312018-05-03$11.24 billion$2.24$2.0310.34%
2017-12-312018-03-31$10.32 billion$2.75$1.15138.91%
2017-09-302017-12-31$1 billion$0.95$1.47-35.41%
2017-06-302017-09-30$3.97 billion$0.62$1.76-64.75%
2017-03-312017-06-30$13.24 billion$1.09$2.30-52.51%
2016-12-312017-03-31$11.82 billion$2.09$1.2074.33%
2016-09-302016-12-31$0.65$1.62-59.94%
2016-06-302016-09-30$1.16$1.98-41.63%
2016-03-312016-06-30$1.21$2.18-44.66%
2015-12-312016-03-31$2.01$1.2659.69%
2015-09-302015-12-31$0.82$1.47-44.52%
2015-06-302015-09-30$1.33$1.85-27.92%
2015-03-312015-06-30$1.53$2.16-29.29%
2014-12-312015-03-31$1.66$1.2136.99%
2014-09-302014-12-31$0.31$1.27-75.83%
2014-06-302014-09-30$1.22
2014-03-312014-06-30$1.51
2013-12-312014-03-31$2.33
2013-09-302013-12-31$0.76
2013-06-302013-09-30$1.20
2013-03-312013-06-30$1.32
2012-12-312013-03-31$1.79
2012-09-302012-12-31$0.58
2012-06-302012-09-30$0.80
2012-03-312012-06-30$0.74
2011-12-312012-03-31$1.68
2011-09-302011-12-31$0.62
2011-06-302011-09-30$1.04
2011-03-312011-06-30$1.31
2010-12-312011-03-31$1.17
2010-09-302010-12-31-$0.24
2010-06-302010-06-30$0.79
2010-03-312010-03-31$1.14
2009-09-302009-09-30$0.42
2009-06-302009-06-30$0.90
2009-03-312009-03-31$0.70
2008-12-312008-12-31$0.34
2008-09-302008-09-30$0.52
2008-06-302008-06-30$1.07
2008-03-312008-03-31$1.36
2007-12-312007-12-31$0.16
2007-09-302007-09-30$1.97
2007-06-302007-06-30$1.10
2007-03-312007-03-31$4.43
2006-12-312006-12-31$0.54

Bayer Aktiengesellschaft (BAYZF) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Bayer Aktiengesellschaft (BAYZF) Chart:

Bayer Aktiengesellschaft (BAYZF) News:

Below you will find a list of latest news for Bayer Aktiengesellschaft (BAYZF) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Bayer Aktiengesellschaft (BAYZF) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Bayer Aktiengesellschaft (BAYZF) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link